Combination of glycolysis inhibition with chemotherapy results in an antitumor immune response
- 19 November 2012
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 109 (49), 20071-20076
- https://doi.org/10.1073/pnas.1206360109
Abstract
Most DNA-damaging agents are weak inducers of an anticancer immune response. Increased glycolysis is one of the best-described hallmarks of tumor cells; therefore, we investigated the impact of glycolysis inhibition, using 2-deoxyglucose(2DG), in combination with cytotoxic agents on the induction of immunogenic cell death. We demonstrated that 2DG synergized with etoposide-induced cytotoxicity and significantly increased the life span of immunocompetent mice but not immunodeficient mice. We then established that only cotreated cells induced an efficient tumor-specific T-cell activation ex vivo and that tumor antigen-specific T cells could only be isolated from cotreated animals. In addition, only when mice were immunized with cotreated dead tumor cells could they be protected (vaccinated) from a subsequent challenge using the same tumor in viable form. Finally, we demonstrated that this effect was at least partially mediated through ERp57/calreticulin exposure on the plasma membrane. These data identify that the targeting of glycolysis can convert conventional tolerogenic cancer cell death stimuli into immunogenic ones, thus creating new strategies for immunogenic chemotherapy.Keywords
This publication has 31 references indexed in Scilit:
- Cancer metabolism: current perspectives and future directionsCell Death & Disease, 2012
- The Transcription Factor Myc Controls Metabolic Reprogramming upon T Lymphocyte ActivationImmunity, 2011
- Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of IdoNature Medicine, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell deathThe EMBO Journal, 2009
- In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomasProceedings of the National Academy of Sciences of the United States of America, 2008
- A catabolic block does not sufficiently explain how 2-deoxy-d-glucose inhibits cell growthProceedings of the National Academy of Sciences of the United States of America, 2008
- Endogenous bcl-2 is not required for the development of Eμ-myc–induced B-cell lymphomaBlood, 2007
- Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphomaProceedings of the National Academy of Sciences of the United States of America, 2007
- The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic miceNature, 1985